{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T15:01:13Z","timestamp":1788966073267,"version":"build-2803163510"},"reference-count":22,"publisher":"Japanese Circulation Society","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ J"],"published-print":{"date-parts":[[2022,6,24]]},"DOI":"10.1253\/circj.cj-21-0926","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T22:09:07Z","timestamp":1646863747000},"page":"1068-1078","source":"Crossref","is-referenced-by-count":15,"title":["Tolerability of the Intravenously Administered Tolvaptan Prodrug, OPC-61815, in Patients With Congestive Heart Failure Who Have Difficulty With, or Are Incapable of, Oral Intake (TRITON-HF)\u3000\u2015 A Phase III, Multicenter, Open-Label Trial \u2015"],"prefix":"10.1253","volume":"86","author":[{"given":"Koichiro","family":"Kinugawa","sequence":"first","affiliation":[{"name":"Second Department of Internal Medicine, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eisuke","family":"Nakata","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Hirano","sequence":"additional","affiliation":[{"name":"Medical Affairs, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seongryul","family":"Kim","sequence":"additional","affiliation":[{"name":"Headquarters of Clinical Development, Otsuka Pharmaceutical Co., Ltd."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017. <i>Lancet<\/i> 2018; 392: 1789\u20131858.","DOI":"10.1016\/S0140-6736(18)32279-7"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Konishi M, Ishida J, Springer J, von Haehling S, Akashi YJ, Shimokawa H, et al. Heart failure epidemiology and novel treatments in Japan: Facts and numbers. <i>ESC Heart Fail<\/i> 2016; 3: 145\u2013151.","DOI":"10.1002\/ehf2.12103"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Shimokawa H, Miura M, Nochioka K, Sakata Y. Heart failure as a general pandemic in Asia. <i>Eur J Heart Fail<\/i> 2015; 17: 884\u2013892.","DOI":"10.1002\/ejhf.319"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. O\u2019Connor CM, Stough WG, Gallup DS, Hasselblad V, Gheorghiade M. Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: Observations from the IMPACT-HF registry. <i>J Card Fail<\/i> 2005; 11: 200\u2013205.","DOI":"10.1016\/j.cardfail.2004.08.160"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Gheorghiade M, Follath F, Ponikowski P, Barsuk JH, Blair JE, Cleland JG, et al. Assessing and grading congestion in acute heart failure: A scientific statement from the acute heart failure committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. <i>Eur J Heart Fail<\/i> 2010; 12: 423\u2013433.","DOI":"10.1093\/eurjhf\/hfq045"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>Eur J Heart Fail<\/i> 2016; 18: 891\u2013975.","DOI":"10.1002\/ejhf.592"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 Guideline on diagnosis and treatment of acute and chronic heart failure: Digest version. <i>Circ J<\/i> 2019; 83: 2084\u20132184.","DOI":"10.1253\/circj.CJ-19-0342"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Palazzuoli A, Ruocco G, Pellegrini M, Beltrami M, Del Castillo G, Nuti R. Loop diuretics strategies in acute heart failure: From clinical trials to practical application. <i>Curr Drug Targets<\/i> 2015; 16: 1246\u20131253.","DOI":"10.2174\/1389450116666150420125531"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mentz RJ, Kjeldsen K, Rossi GP, Voors AA, Cleland JG, Anker SD, et al. Decongestion in acute heart failure. <i>Eur J Heart Fail<\/i> 2014; 16: 471\u2013482.","DOI":"10.1002\/ejhf.74"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Gottlieb SS, Brater DC, Thomas I, Havranek E, Bourge R, Goldman S, et al. BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. <i>Circulation<\/i> 2002; 105: 1348\u20131353.","DOI":"10.1161\/hc1102.105264"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al. Diuretic strategies in patients with acute decompensated heart failure. <i>N Engl J Med<\/i> 2011; 364: 797\u2013805.","DOI":"10.1056\/NEJMoa1005419"},{"key":"12","unstructured":"12. Yamamura Y, Nakamura S, Itoh S, Hirano T, Onogawa T, Yamashita T, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: Pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. <i>J Pharmacol Exp Ther<\/i> 1998; 287: 860\u2013867."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Udelson JE, Bilsker M, Hauptman PJ, Sequeira R, Thomas I, O\u2019Brien T, et al. A multicenter, randomized, double-blind, placebo-controlled study of tolvaptan monotherapy compared to furosemide and the combination of tolvaptan and furosemide in patients with heart failure and systolic dysfunction. <i>J Card Fail<\/i> 2011; 17: 973\u2013981.","DOI":"10.1016\/j.cardfail.2011.08.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Matsue Y, Ter Maaten JM, Suzuki M, Torii S, Yamaguchi S, Fukamizu S, et al. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction. <i>Clin Res Cardiol<\/i> 2017; 106: 802\u2013812.","DOI":"10.1007\/s00392-017-1122-1"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Matsuzaki M, Hori M, Izumi T, Fukunami M, Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: A phase III, randomized, double-blind, placebo-controlled study (QUEST study). <i>Cardiovasc Drugs Ther<\/i> 2011; 25(Suppl 1): S33\u2013S45.","DOI":"10.1007\/s10557-011-6304-x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Kuragaichi T, Sato Y. Temporal trends of a vasopressin V2 receptor antagonist in heart failure using a nationwide database in Japan. <i>ESC Heart Fail<\/i> 2021; 8: 527\u2013538.","DOI":"10.1002\/ehf2.13111"},{"key":"17","unstructured":"17. Otsuka Pharmaceutical Co., Ltd. Jynarque: Highlights of prescribing information. https:\/\/www.otsuka-us.com\/media\/static\/JYNARQUE-PI.pdf (accessed June 5, 2021)."},{"key":"18","unstructured":"18. Otsuka Pharmaceutical Co., Ltd. Samsca: Highlights of prescribing information. https:\/\/www.otsuka-us.com\/media\/static\/Samsca-PI.pdf (accessed June 5, 2021)."},{"key":"19","unstructured":"19. Center for Drug Evaluation and Research. Jynarque: Clinical pharmacology review. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/204441Orig1s000ClinPharmR.pdf (accessed June 5, 2021)."},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Sica DA. Diuretic-related side effects: Development and treatment. <i>J Clin Hypertens (Greenwich)<\/i> 2004; 6: 532\u2013540.","DOI":"10.1111\/j.1524-6175.2004.03789.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Kinugawa K, Sato N, Inomata T, Yasuda M, Shimakawa T, Fukuta Y. Real-world effectiveness and tolerability of tolvaptan in patients with heart failure: Final results of the Samsca post-marketing surveillance in heart failure (SMILE) study. <i>Circ J<\/i> 2019; 83: 1520\u20131527.","DOI":"10.1253\/circj.CJ-19-0158"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sato N, Uno S, Yamasaki Y, Hirano T, Kim S; on behalf of the OPC-61815 Investigators. Pharmacokinetics, pharmacodynamics, efficacy, and safety of OPC-61815, a prodrug of tolvaptan for intravenous administration, in patients with congestive heart failure: A Phase II, Multicenter, Double-Blind, Randomized, Active-Controlled Trial. <i>Circ J<\/i> 2022; 86: 699\u2013708.","DOI":"10.1253\/circj.CJ-21-0430"}],"container-title":["Circulation Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/7\/86_CJ-21-0926\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T04:44:51Z","timestamp":1656132291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circj\/86\/7\/86_CJ-21-0926\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6,24]]},"references-count":22,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1253\/circj.cj-21-0926","relation":{},"ISSN":["1346-9843","1347-4820"],"issn-type":[{"value":"1346-9843","type":"print"},{"value":"1347-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,24]]},"article-number":"CJ-21-0926"}}